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ABSTRACT 
Despite advances in multimodality treatment, surgery remains the mainstay of curative 
treatment for oesophageal cancer. However short- and long-term mortality from 
oesophagectomy for oesophageal cancer still shows large variations nationally and 
internationally.  
This thesis addresses three themes concerning oesophageal cancer surgery. The first theme 
focuses on technical challenges, learning in surgery and the influence of surgeon age on 
outcomes from oesophagectomy. Study I utilised a large French multi-centre database 
(FREGAT), and showed in contrast to previous smaller single-centre studies, salvage 
oesophagectomy after definitive chemoradiotherapy can offer acceptable short- and long-
term outcomes in selected patients at experienced oesophageal cancer centres. Study II 
used a national Swedish dataset (SESS) and demonstrated that the period during which 
surgeons gain proficiency in performing oesophagectomy for cancer is associated with 
substantial adverse effects upon short- and long-term mortality at a national level. The 
length of the proficiency gain period was longer for long-term mortality than for short-term 
mortality, implying a change in surgeon focus during the initial stages of their independent 
practice. Study III also used the SESS and was able to show the optimal surgeon age in 
performing oesophagectomy in Sweden is between 51 and 56 years. Outside of this age 
period, increases in short- and long-term mortality are noted, as surgeons are still gaining 
experience or maybe experiencing decline in their technical abilities.  
The second theme, sought to evaluate the effect of hospital factors, which may affect 
outcome from oesophagectomy for cancer. Study IV used SESS once more, and showed 
surgery performed in university hospitals has no improvements in long-term mortality from 
oesophagectomy after adjustment for surgeon volume and other confounders.  
The third theme of this thesis considered the effect of complications during treatment for 
oesophageal cancer upon long-term prognosis. Study V used FREGAT and demonstrated 
severe oesophageal anastomotic leak following oesophagectomy for cancer, adversely 
impacts cancer prognosis with a decrease in overall and disease-free survival and an 
increasing in overall, loco-regional and mixed cancer recurrence.  
In conclusion, the studies conducted within this thesis have shown the safety of new 
therapeutic surgical strategies for oesophageal cancer, the importance of surgeon 
proficiency gain and surgeon age in prognosis, the lack of significance of university 
hospital status, and the adverse long-term prognostic effects of severe oesophageal 
anastomotic leak.  
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1 INTRODUCTION 
Oesophageal cancer is in the top five most rapidly rising cancers in the Western World and 
in Europe has an age-standardized incidence rate of 4.7 per 100,000 individuals. In its early 
stages oesophageal cancer grows slowly and often presents with non-specific upper 
gastrointestinal symptoms. As a result the majority of patients present with advanced 
disease and have a poor survival. The minority of patients with less advanced disease are 
considered for curative treatment with surgical resection with or without neoadjuvant 
chemotherapy or combined chemoradiotherapy.  
Recent randomized controlled trials have focused on the addition of neoadjuvant therapy to 
surgery to improve long-term survival, or in some cases primary (definite) treatment with 
chemoradiotherapy. However, surgery remains the mainstay of curative treatment for 
oesophageal cancer, despite this is a highly invasive procedure with considerable treatment-
related mortality and morbidity. The principal aim of this thesis was to evaluate treatment, 
surgeon and hospital related factors along-with postoperative complications that may affect 
survival in patients undergoing surgery for oesophageal cancer. 
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2 BACKGROUND 
2.1. Oesophageal cancer 
The incidence of oesophageal cancer is increasing annually; representing 7% of all 
gastrointestinal malignancies internationally [1–3]. In 2012 the number of new cases of 
oesophageal cancer across Europe was 45,900 with an age-standardized incidence rate of 
4.7 per 100,000 individuals [4]. Oesophageal cancer is broadly defined into two main 
histological subtypes, squamous cell carcinoma and adenocarcinoma. In Far Eastern 
countries the most common subtype is oesophageal squamous cell carcinoma (OSCC), and 
given the high incidence in these countries, OSCC remains the most common histological 
subtype worldwide [5]. Risk factors for OSCC include tobacco smoking, overconsumption 
of alcohol, achalasia, drinking very hot liquids, low dietary intake of fruit and vegetables 
and receiving radiation to upper chest and abdomen. During the recent four decades there 
has been a rapid rise in the incidence of oesophageal adenocarcinoma (OA) in the Western 
world. This tumour is associated with gastro-oesophageal reflux disease (GORD), increased 
body mass index, low dietary intake of fruit and vegetables and tobacco smoking, while 
infection with Helicobacter pylori is inversely associated with this tumour [6,7].  The 
pathogenesis of OA is typically initiated by long-standing acidic insult caused by GORD to 
the lower oesophagus, which causes a metaplastic change in the epithelium from squamous 
cell to a glandular-type specialised columnar epithelium, entitled Barrett’s oesophagus. The 
ongoing acidic insult to the lower oesophagus can further cause dysplastic change in these 
metaplastic cells and eventually progression to invasive OA [8–10]. Therefore these two 
histological subtypes differ in their location with typically OSCC affecting any part of the 
oesophagus and OA affecting almost exclusively the lower part of the oesophagus [11,12].  
Early diagnosis of oesophageal cancer allows treatment at an earlier stage of disease, which 
has been shown to translate into a substantial improvement in five-year survival (up 80%) 
[13]. However often the disease presents in a non-specific fashion with more specific 
symptoms (dysphagia and weight loss) only occurring at more advanced cancer stages and 
carrying a much poorer prognosis [14]. The overall European pooled relative 1-year and 5-
year survival rates for oesophageal cancer from the EUROCARE-4 study have previously 
been shown to be approximately 33.4% (95%CI 32.9–33.9%) and 9.8% (95%CI 9.4–
10.1%) respectively [15], illustrating this diagnostic issue. In the current era, most patients 
with oesophageal cancer are diagnosed first after cardinal symptoms are evident and only 
one third of patients, mainly those without distant metastasis and with reasonably good 
fitness, are considered eligible for curative treatment [16].  
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2.2. Surgical treatment of oesophageal cancer 
Oesophagectomy for cancer often involves thoracotomy and laparotomy with resection of 
most of the oesophagus, formation of a gastric conduit (made into a tube), which is then 
translocated to the thorax or neck for anastomosis.  This is a highly morbid procedure, 
which carries a 30-day mortality rate ranging from 2% to 8% in the current era [17] and 
high rates (40-60%) of postoperative complications and substantial impact upon patients’ 
functional status and health-related quality of life [18–20]. In more recent years, some 
surgeons have employed minimally invasive techniques to oesophagectomy and 
demonstrated reduced pulmonary morbidity within a randomised trial setting [21], and 
reduced mortality at a national level [22].  
 
2.3. Multimodality treatment of oesophageal cancer 
Multimodality treatment has become the standard of care in Western centres for locally 
advanced oesophageal cancer. Two neoadjuvant approaches have been adopted. The first is 
neoadjuvant chemoradiotherapy, based in recent years on the regimen evaluated in a large 
and influential randomised clinical trial from the Netherlands (CROSS), which resulted in a 
5-year survival advantage of 14% in comparison to surgery alone [23,24]. An alternative 
option is perioperative or preoperative chemotherapy using the protocol from two other 
well-designed randomised clinical trials (MAGIC and OEO2), which showed respectively 
5-year survival improvements of 13% and 6% compared to surgery alone [25,26]. The 
maximum benefit in the CROSS-trial was observed in OSCC, with highly significant 
benefit compared to surgery alone (hazard ratio [HR] 0.48; 95% confidence interval [CI] 
0.28–0.83; p=0.009). In OA, the benefit was more modest (HR=0.73; 95%CI 0.55–0.98; 
p=0.037). However, the benefit of neoadjuvant chemoradiotherapy was consistent across 
subgroups, without any significant interactions identified [23,24]. Two other smaller 
randomised clinical trials comprising 119 and 75 patients with OA did not show any 
significant difference in survival between neoadjuvant chemoradiotherapy plus surgery and 
neoadjuvant chemotherapy plus surgery [27,28]. The recently reported NeoRES trial in a 
mixed cohort of 181 patients with OA or OSSC, showed pathological benefits without any 
changes in survival associated with the addition of radiotherapy to neoadjuvant 
chemotherapy [29]. Taken together, the current weight of evidence suggests a prognostic 
benefit to the utilisation of neoadjuvant chemoradiotherapy for OSCC, however any 
prognostic difference between neoadjuvant chemoradiotherapy and chemotherapy for OA 
remains to be established and is the subject of ongoing trials.  
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2.4. Salvage oesophagectomy 
Current National Comprehensive Cancer Network (NCCN) and French guidelines state 
definitive chemoradiotherapy (dCRT) without surgery is an alternative to neoadjuvant 
chemoradiotherapy and resectional surgery (NCRS) for locally advanced OSCC [30]. 
Previous randomised controlled trials have demonstrated equivalence in 2-year survival for 
patients with OSCC treated by NCRS and those treated with dCRT [31,32]. However local 
recurrence rates are high (40–75%) following dCRT [33–35]. These groups of patients with 
persistent or recurrent disease are selectively considered for salvage oesophagectomy. Use 
of dCRT can adversely impact patient performance status [36,37], and together with the 
effects of high radiation doses upon thoracic tissue places as well as radiation effects on 
cardiac and pulmonary function, this can make salvage oesophagectomy a considerable 
challenge. In a meta-analysis of 8 retrospective studies comprising 254 patients suggested 
salvage oesophagectomy was associated with increased mortality, anastomotic leak, 
pulmonary complications and length of hospital stay when compared to NCRS [38]. 
However with the total number of patients in the salvage oesophagectomy group ranging 
from 14 to 65 for the studies included, it may be suggested this analysis was based upon 
small series of patients from historical studies, and there is a need for a prospective 
randomised controlled trial.  
 
2.5. Proficiency-gain curve 
A critical challenge in the introduction of complex surgical techniques is the proficiency-
gain curve while surgeons gain experience in performing new procedures. A review of 23 
published studies suggested that the proficiency-gain curve for laparoscopic colorectal 
surgery is approximately 88 to 152 cases, when considering complications, operative time, 
blood loss and length of hospital stay [39]. Similarly, a proficiency-gain curve has been 
observed in oesophageal and gastric cancer surgery [40,41]. While significant improvement 
is expected with new techniques, learning at the expense of patient safety and prognosis 
remains a major clinical and ethical consideration. The majority of studies regarding 
proficiency-gain curves originate from individual surgeons or single institutions, which do 
not reflect the real clinical environment for the uptake of new techniques at a population 
level. I have previously co-authored a study on the national proficiency-gain curve in the 
United Kingdom in minimal access surgery that described measurable effects upon short-
term clinical outcomes following oesophageal and colorectal cancer resections as surgeons 
gain proficiency [42].  
17
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2.6. Surgeon age 
Oesophagectomy is a technically demanding and time-consuming procedure with higher 
rates of mortality and morbidity than most other surgical procedures [43,44]. The physical 
and psychological abilities required for oesophagectomy may change with increasing 
surgeon age. Government regulatory bodies often specify the retirement age threshold with 
a primary emphasis on balancing the workforce, and thus physicians in medical and 
surgical specialties have a similar retirement age, despite the high technical demands for 
complex surgery [45,46]. As individual surgeons age their risk-taking behaviour and levels 
of confidence might change, which may be reflected in surgical practice [47,48]. Yet, there 
is very limited evidence of the role of surgeon age on patient outcomes from surgery. One 
previous publication suggested that older surgeon age may negatively influence in-hospital 
mortality from selected procedures, including pancreatectomy, coronary artery bypass 
grafting, and carotid endarterectomy [49]. No previous study has examined the influence of 
surgeon age upon long-term prognosis following any type of cancer surgery, and 
oesophagectomy may be of particular relevance in this respect. 
 
2.7. Hospital and service structure related factors  
In recent years there has been steady improvement in outcome parameters including 
postoperative mortality following oesophagectomy for oesophageal cancer [50–52]. The 
reasons for this improvement are multi-factorial but include better patient selection, 
preoperative optimisation, centralisation of services, advances in surgical technique and 
improvements in perioperative care [17,53]. The centralisation of oesophageal cancer 
surgical services to high volume centres with the appropriate infrastructure to manage these 
complex patients and deliver a consistently high level of care has been shown to reduce 
oesophagectomy associated morbidity and mortality [43,44,54]. Thus the volume-outcome 
effect in the setting of oesophagectomy is well established and has influenced policy and 
outcome through centralisation in many countries worldwide. However more specific 
factors of these high volume centres that may be responsible for the improvement in 
outcomes have only been evaluated to a limited extent previously.  
 
2.8. Complications during treatment of oesophageal cancer  
Complications following oesophagectomy for cancer have been suggested to have an 
adverse prognostic impact upon disease recurrence and thus long-term survival. A study of 
18
  7 
531 patients with a focus on technical complications suggested that of all technical 
complications, anastomotic leak had the largest impact on long-term survival [55]. 
Conversely an analysis of 567 patients, 47 of whom developed an anastomotic leak, found 
no effect on long-term survival (median 22.0 vs. 24.4 months) [56]. Meta-analysis of large 
datasets from the colorectal cancer surgery literature have suggested that anastomotic leak 
following resection had a negative prognostic impact on local recurrence and reduced long-
term cancer specific survival, with no effect on distant recurrence [57]. Previously authors 
have suggested that for colorectal surgery, colorectal cancer cells are detectable in the 
bowel lumen and on the suture or staple lines during resection, with in vitro and animal 
models demonstrating these cells retain their metastatic potential [58,59]. Leakage of 
enteric contents sets up a pro-inflammatory environment with the release of a variety of 
acute phase reactants and cytokines stimulating local recurrence and poorer survival 
[58,59]. Therefore there is a scientific rationale for the adverse impact of anastomotic leak 
on survival from oesophagectomy, although there remain conflicting published results. As 
the utilisation of neoadjuvant therapy has become an increasingly common component of 
the multi-modality management of patients with oesophageal cancer, it becomes more 
important to consider the potential adverse effects of neoadjuvant regimes. Some 
researchers have suggested an increase in the incidence of anastomotic leak after 
neoadjuvant chemoradiotherapy, possibly due to the ischaemic effects of radiotherapy upon 
the microcirculation of the gastric conduit [60, 61]. 
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3 AIMS OF THE STUDIES 
The main aim of this thesis was to extend the body of knowledge on treatment, surgeon and 
hospital related factors along-with postoperative complications that may affect survival in 
patients undergoing surgery for oesophageal cancer. 
Specific aims were:  
• To assess the impact of salvage oesophagectomy after definitive chemoradiotherapy on 
clinical outcomes.  
• To identify the presence and length of oesophagectomy proficiency gain curves in terms 
of short- and long-term mortality for oesophageal cancer.  
• To evaluate the effect of surgeon age upon short- and long-term mortality from 
oesophagectomy for cancer.  
• To consider how management in a university hospital affects prognosis following surgery 
for oesophageal cancer.  
• To determine the impact of severe oesophageal anastomotic leak upon long-term survival 
and loco-regional cancer recurrence. 
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4 MATERIALS AND METHODS 
4.1 OVERVIEW 
Table 1. Over of the material and methods used in studies I–V.  
 Study I Study II Study III Study IV Study V 
Design Population-based cohort study 
Data sources French 
esophagogastric 
(FREGAT) 
database  
Swedish Esophageal Cancer Surgery 
Study (SESS), including data from 
the Swedish Cause of Death Registry, 
Cancer Registry, Patient Registry and 
medical records.  
French 
esophagogastric 
(FREGAT) 
database 
Cohort Patients 
undergoing 
oesophagectomy 
for oesophageal 
cancer in 30 
French-speaking 
university 
hospitals 
Swedish residents undergoing 
oesophagectomy for oesophageal 
cancer  
Patients 
undergoing 
oesophagectomy 
for oesophageal 
cancer in 30 
French-speaking 
university 
hospitals 
Inclusion 
period 
1st Jan 2000 to 
31st Dec 2010 
1st Jan 1987 to 31st Dec 2010 1st Jan 2000 to 
31st December 
2010 
Follow-up 1st Jan 2000 to 
15th Jul 2013 
1st Jan 1987 to 31st Nov 2014 1st Jan 2000 to 
15th Jul 2013 
Exposure Salvage 
oesophagectomy 
Proficiency 
gain curve 
Surgeon 
age 
University 
hospital 
Anastomotic leak 
Outcome 3-year overall 
and disease-free 
survival 
90-day and 5-year all-cause and 
disease-specific mortality 
Long-term 
survival and 
recurrence 
Confounders Age, sex, ASA, 
tumour stage, 
Age, sex, medical comorbidities 
tumour stage, histology, neoadjuvant 
Age, sex, ASA, 
tumour stage, 
23
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histology and 
location, hospital 
volume, surgical 
technique 
therapy, surgeon volume (IV), 
calendar period (IV) 
histology and 
location, hospital 
volume, surgical 
technique, 
neoadjuvant 
therapy 
Main 
statistical 
methods  
Propensity score 
matching, 
Logistic and Cox 
regression 
Risk adjusted 
cumulative sum analysis 
Cox 
regression 
Logistic and Cox 
regression 
 
4.2. DATA SOURCES  
The studies included in this thesis are based upon two large databases gathered by research 
groups over several years: (i) French esophagogastric (FREGAT) database and (ii) Swedish 
Esophageal Cancer Surgery Study (SESS).  
 
4.2.1. French esophagogastric (FREGAT) database 
The FREGAT database includes data from 2944 consecutive patients (aged 18 years or 
older) undergoing surgical resection for oesophageal cancer (including Siewert type I and II 
junctional tumours) with a curative intent in 30 French-speaking European centres between 
2000 and 2010. Data were retrospectively collected through a dedicated website 
(http://www.chirurgie-viscerale.org), with an independent monitoring team auditing data 
capture to minimise missing data and to ensure concordance, and inclusion of consecutive 
patients. Data collected included patient demographic factors, preoperative and surgical 
treatments, postoperative outcomes, histopathological results and long-term oncological 
outcomes. Missing or inconsistent data were obtained from email exchanges or telephone 
calls with the treating centre.   
 
4.2.2. Swedish Esophageal Cancer Surgery Study (SESS). 
The Swedish Esophageal Cancer Surgery Study (SESS) is a retrospective cohort of almost 
all patients in Sweden receiving surgery for primary oesophageal cancer from 1987 to 
2010, with follow-up until 31st November 2014. Patients with a diagnosis of oesophageal 
cancer were identified from the Swedish Cancer Registry. These patients were then linked 
with the Swedish Patient Registry to identify those who underwent surgery for oesophageal 
cancer during the study period. The Swedish personal identity number, assigned to each 
24
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Swedish resident at birth or immigration was used to link data between registries and in the 
identification of individual medical records. Hospital and histopathology records for 
eligible patients were retrieved from all Swedish hospitals where oesophageal cancer 
surgery was performed and these records were manually reviewed according to predefined 
protocols to ensure uniformity. Clinical data on tumour and treatment characteristics were 
collected through a nationwide Swedish clinical network established in the 1990s. Data 
concerning neoadjuvant therapy, names of surgeons, date of surgery, pathological tumour 
stage, and histological subtype were obtained from review of individual patient medical 
records. Information about death and causes of death was available from the Swedish Cause 
of death Registry.  
 
4.3. DATA SOURCES INCLUDED IN SESS 
4.3.1. The Swedish Cancer Registry 
The Swedish Cancer Registry was established in 1958, with all Swedish healthcare 
providers (both public and private) required to report new cancer cases to the registry. 
Cancer diagnoses based on clinical, morphological, or histopathological examination are 
registered according to the International Classification of Diseases seventh edition, for 
oesophageal cancer (150.0, 150.8 and 150.9). Diagnoses based on autopsies are reported 
but not registered. The Swedish Cancer Registry has 98% nationwide coverage of 
oesophageal cancer cases in Sweden, and histopathological confirmation of these tumours 
has been shown to be 100% complete [62, 63]. 
 
4.3.2. The Swedish Patient Registry 
The Swedish Patient Registry was initiated in 1964 for the collection of data regarding in-
hospital care of patients in Sweden. From 1987, participation in the registry was mandatory 
for all Swedish hospitals, allowing calculation of a nationwide completeness rate ever 
since. Patients with oesophageal cancer who received oesophagectomy were identified from 
this registry, which has an excellent positive identification rate (99.6%) for oesophageal 
surgery [63]. This registry also provided data regarding patient medical comorbidities and 
reoperations.  
 
4.3.3. The Swedish Causes of Death Registry 
Since 1952, this registry has provided data on all deaths of Swedish residents, whether in 
Sweden or abroad. The contributing cause(s) of death using the most recent version of ICD, 
and date of death are reported in a death certificate issued by the treating physician. The 
25
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registry covers more than 99% of all deaths in Sweden since 1952 [64].  
 
4.4. STUDY DESIGN 
4.4.1. Study I 
This retrospective cohort study investigated the impact of salvage oesophagectomy 
following definitive chemoradiotherapy upon short and long-term clinical outcomes 
compared with neoadjuvant chemoradiotherapy and planned surgery (NCRS) for patients 
who underwent surgery between 2000 and 2010, with follow-up until 15th July 2013, from 
the FREGAT database. A subset comparison of short and long-term clinical outcomes for 
patients within the salvage oesophagectomy group receiving treatment for persistent or 
recurrent oesophageal cancers was also conducted.  
 
4.4.2. Study II 
Using the SESS dataset, this population-based cohort study investigated the length and 
clinical implications of the proficiency gain curve for surgeons performing open 
oesophagectomy for oesophageal cancer from 1987 to 2010, with follow-up until 
November 2014, in terms of short- and long-term mortality within Sweden. 
 
4.4.3. Study III 
This population-based cohort study utilised the SESS dataset to investigate the effect of 
surgeon age upon short and long-term mortality from oesophagectomy for oesophageal 
cancer from 1987 to 2010, with follow-up until 31st May 2016,  within Sweden. 
 
4.4.4. Study IV 
A population-based cohort study design was used to evaluate the effect of surgery 
performed in university hospitals upon short and long-term mortality from oesophagectomy 
for oesophageal cancer from 1987 to 2010, with follow-up until November 2014, within 
Sweden. The study used data from the SESS dataset.  
 
4.4.5. Study V 
The FREGAT database was used to investigate the impact of severe oesophageal 
anastomotic leak upon long-term survival and tumour recurrence following 
oesophagectomy performed between 2000 and 2010, with follow-up until 15th July 2013, 
for oesophageal cancer. The association between patient, tumour and treatment-related 
factors, and severe oesophageal anastomotic leak was also evaluated within this study.  
26
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4.5. EXPOSURES 
4.5.1. Study I 
The exposure in this study was salvage oesophagectomy defined as removal of the 
oesophagus for persistent or recurrent disease within the tumour or loco-regional lymph 
nodes after definitive chemoradiotherapy.  
 
4.5.2. Study II 
The exposure was period of surgeon proficiency gain in performing open oesophagectomy 
for oesophageal cancer.  
 
4.5.3. Study III 
The exposure in this study was the age of the surgeon at the time of oesophagectomy for 
each patient. This age was calculated from the date of birth of each surgeon and the date of 
each operation.  
 
4.5.4. Study IV 
The exposure investigated was oesophagectomy performed in any of the six Swedish 
university hospitals compared to non-university hospitals.  
 
4.5.5. Study V 
The exposure in this study was severe oesophageal anastomotic leak. This was defined as a 
symptomatic (mediastinal abscess, mediastinitis or digestive content in the chest drain) 
disruption of the intrathoracic anastomosis, classified as grade III or IV according to the 
Clavien-Dindo classification [65].  
 
4.6. OUTCOMES 
4.6.1. Study I 
The outcomes evaluated in this study included in-hospital mortality and morbidity, 3-year 
overall and disease-free survival and overall, mixed and loco-regional cancer recurrence. 
In-hospital morbidity was sub-classified and analysed as anastomotic leak, conduit 
necrosis, surgical site infection, chylothorax, postoperative haemorrhage, gastroparesis, 
pulmonary, cardiovascular, thromboembolic and neurologic with severity graded according 
to the Clavien-Dindo classification [65]. 
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4.6.2. Study II 
The main outcomes studied were 30-day, 90-day, 1-year, 3-year and 5-year all-cause and 
disease-specific mortality, all calculated from the date of surgery. Additional outcomes 
evaluated included lymph node harvest, resection margin status and incidence of 
reoperation.  
 
4.6.3. Study III 
The outcomes analysed in this study were all-cause 90-day and 5-year mortality and 
disease-specific 5-year mortality, all calculated from the date of surgery.  
 
4.6.4. Study IV 
Similarly the outcomes analysed in this study were all-cause 90-day and 5-year mortality 
and disease-specific 5-year mortality, all calculated from the date of surgery. 
 
4.6.5. Study V  
The main outcomes of this study were overall and disease-free survival, along-with overall, 
local, distant and mixed tumour recurrence. The secondary outcomes of the study were the 
identification of preoperative and intraoperative factors associated with severe oesophageal 
anastomotic leak.  
 
4.7. STATISTICAL ANALYSIS 
4.7.1. Study I 
For crude analyses, Mann-Whitney U test was used for intergroup comparisons of 
continuous variables, chi-squared or Fisher’s exact tests were used to compare categorical 
data, and overall and disease-free survivals were estimated by the Kaplan-Meier method. A 
propensity score was calculated to develop well-balanced groups and reduce any effects of 
potential confounding factors in short- and long-term outcomes analysis. A multivariable 
logistic regression model was used to estimate the propensity score, with the study groups 
as the dependent variables and all potential confounders as covariates. Confounders 
included in this model were surgery after 2006 (yes or no), age 60 years or more (yes or 
no), male sex (yes or no), ASA score (1, 2, 3 or 4), centre volume ≥80 (yes or no), tumour 
location (upper, middle or lower), clinical TNM stage (I, II, III or IV), surgical technique 
(Ivor Lewis, three stage or transhiatal oesophagectomy), and tumour histology (squamous 
cell carcinoma or adenocarcinoma). Patients in the salvage oesophagectomy group were 
matched in a 1:1 ratio with patients from the NCRS group according to the propensity score 
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using the global optimum method. Short and long-term outcomes between the matched 
groups were compared using logistic regression or Cox-regression models using the robust 
sandwich estimate for the matched sets. These models allowed the generation of odds ratios 
(ORs) and HRs as effect-size measures with 95% CIs. The comparison within the salvage 
oesophagectomy group of persistent and recurrent oesophageal cancer cases had a very 
small sample size and therefore the propensity score was used to adjust the analysis rather 
than a formal matching process. Adjustment was performed using multivariable logistic 
regression or Cox regression models include the propensity score as a covariate within the 
model.  
 
4.7.2. Study II 
The primary method of analysis used in this study was Risk Adjusted Cumulative Sum 
(RA-CUSUM) curves [66] to evaluate changes in mortality associated with increase case 
number or proficiency gain. Logistic regression models were used to create risk prediction 
models for the binary outcomes (mortality, reoperation and resection margin), and calculate 
the predicted probability of each outcome for individual cases. Potential confounding 
factors included in the models were age (continuous variable), sex (male or female), tumour 
histological subtype (adenocarcinoma or squamous cell carcinoma), pathological stage 
(stage I, II, III or IV), use of neoadjuvant therapy (yes or no), and individual pre-operative 
co-morbidities (yes or no). RA-CUSUM curves plot the cumulative difference between the 
observed and expected outcome. This was calculated using the CUSUM equation Si=Si-1+( 
Σ i- ΣR); S0=0: Si is the cumulative sum, Σ i the sum of events at procedure number i, and 
ΣR the sum of expected events at procedure number i. On the basis of this equation the 
curve increases if the observed exceeds the expected outcome and vice versa. The change-
points in the curve were identified as the maximal deflection of the curve from 0. Mann-
Whitney U test was used for continuous variables and chi-squared test was used for 
categorical data to compare outcomes before and after the change-point.  
 
4.7.3. Study III 
Similarly to study II, RA-CUSUM was used as the primary method of analysis to evaluate 
changes in mortality associated with operating surgeon age. Again similarly confounding 
factors were included in the logistic regression model to generate the expected probability 
of mortality, age (continuous variable), sex (male or female), comorbidity (Charlson 
comorbidity score 0, 1 or ≥2), pathological tumour stage (0 or I, II, III or IV), tumour 
histology (adenocarcinoma or squamous cell carcinoma), and use of neoadjuvant therapy 
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(yes or no). Surgeon age was seen to strongly correlate with surgeon volume and year of 
surgery so these were included in subsequent Cox regression analyses. As before change-
points in surgeon age affecting mortality were identified by RA-CUSUM curve analysis. 
These were then analysed in relation to the mortality outcomes also using a multivariable 
Cox-proportional hazards model, providing HRs with 95%CIs. Co-variates included in this 
model were the six factors above and cumulative surgeon volume of esophagectomies 
during study period (≤16 or >16) and calendar period of surgery (year 1987–1994, 1995–
2002 or 2003–2010). 
 
4.7.4. Study IV 
Unadjusted Kaplan Meier survival analysis was conducted to visualise the effect of 
university hospital status on crude all-cause and disease-specific mortality within 5 years of 
surgery. University hospital status was analysed in relation to mortality using a 
multivariable Cox-proportional hazards model, providing HRs with 95% CIs, adjusted for 
eight potential confounding factors. Two Cox regression models were created with 
adjustment for the factors below: Model (a); age (continuous), sex (male or female), tumour 
stage (0-I, II or III-IV), Charlson co-morbidity index (0, 1 >1), neoadjuvant therapy (yes or 
no), histological subtype (adenocarcinoma or squamous cell carcinoma), surgeon volume 
(<6, 7 – 16 or 17 – 46), and calendar period (1987 – 1994, 1995 – 2002 or 2003 – 2010). 
Model (b); age (continuous), sex (male or female), tumour stage (0-I, II or III-IV), Charlson 
co-morbidity index (0, 1 or >1), neoadjuvant therapy (yes or no), histological subtype 
(adenocarcinoma or squamous cell carcinoma), and calendar period (1987 – 1994, 1995 – 
2002 or 2003 – 2010). 
 
4.7.5. Study V  
Patients were categorised into those who developed a severe oesophageal anastomotic leak 
and those that did not. Crude analysis comprised Mann-Whitney U test used for intergroup 
comparisons of continuous variables, chi-squared or Fisher’s exact tests used to compare 
categorical data, and overall and disease-free survivals were estimated by the Kaplan-Meier 
method. The factors associated with survival were analysed by Cox proportional hazard 
regression analysis using a stepwise procedure. Binary logistic regression modelling was 
used to identify factors associated with tumour recurrence.  
 
4.8. ETHICAL CONSIDERATIONS 
All studies conducted as part of this research were from either the SESS in Sweden 
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database or the FREGAT database in France. In each study all patients are anonymised. All 
data were retrieved and stored on safe servers at the Karolinska Institutet, University 
Hospital Lille or Imperial College London, and the risk for data leakage is negligible.  
One further ethical concern specific to the Swedish cohort study (SESS) is that patients are 
not explicitly asked to be included. All individuals residing in Sweden are included in 
registries regarding birth and death, hospital attendances, diagnoses and operations. 
Therefore the data from Sweden included with the studies I have described were retrieved 
without the consent of the individual patient. However given the anonymisation of these 
data and the benefits of this type of research, which allow patients to be followed up for a 
long time, providing sufficient sample sizes to study rare subsets and treatment algorithms 
for oesophageal cancer, it is ethically acceptable to conduct this type of research. The 
FREGAT dataset was collected with all patients consented to allow their information to be 
included within the database and used for this exact purpose of research, and therefore no 
additional ethical concerns are raised from this dataset. 
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5 RESULTS 
 
5.1. Study I 
Propensity matched analysis matched 308 patients undergoing salvage oesophagectomy 
following definitive chemoradiotherapy with 308 undergoing planned oesophagectomy 
following neoadjuvant chemoradiotherapy. There were no significant differences between the 
groups in the incidence of in-hospital mortality (OR=0.719, 95%CI 0.414-1.25) or morbidity 
(OR=1.117, 95%CI 0.818-1.525), with the exception of anastomotic leak (OR=1.732, 95%CI 
1.110-2.703) and surgical site infection (OR=1.614, 95%CI 1.058-2.461). There were no 
significant differences between groups in 3-year overall (Figure 1) or disease free survival, or 
overall, loco-regional, distant or mixed cancer recurrence. Within the salvage 
oesophagectomy group, when compared to patients with recurrent disease, those with 
persistent disease showed reduced 3-year overall and disease-free survival and increased 
overall, loco-regional, distant mixed tumour recurrence (Table 1).  
 
3-year outcome  Persistent cancer 
(%) 
Recurrent cancer 
(%) 
P value 
Survival 
Overall  39.1 56.2 0.086 
Disease-free  35.4 51.6 0.09 
Tumour recurrence 
Overall 51.1 39.4 0.136 
Loco-regional 20.6 13.9 0.233 
Distant 26.5 18.7 0.64 
Mixed  15.5 6.9 0.339 
Table 1: Comparison of 3-year outcomes for patients undergoing salvage oesophagectomy 
for persistent or recurrent oesophageal cancer. 
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Figure 1: Comparison of overall survival in propensity matched salvage oesophagectomy 
following definitive chemoradiotherapy and the neoadjuvant chemoradiotherapy followed by 
planned oesophagectomy groups.  
5.2. Study II 
This study included 1820 patients with oesophageal cancer who received oesophagectomy 
performed by a 139 surgeons. RA-CUSUM analysis of 30-day and 90-day all-cause mortality 
showed change-points in the proficiency gain curves at 15 and 22 cases, respectively, after 
which, 30-day all-cause mortality decreased from 7.9% to 3.1% (P<0.001) (Figure 2) and 90-
day all-cause mortality decreased from 7.3% to 5.2% (P=0.079). RA-CUSUM analysis of 3-
year and 5-year all-cause mortality showed change-points in the proficiency gain curves at 35 
and 59 cases, respectively, after which, 3-year all-cause mortality decreased from 47.4% to 
41.5% (P=0.039), and 5-year all-cause mortality decreased from 31.4% to 19.1% (P=0.006) 
(Figure 3). Analyses of tumour involvement in the resection margin (R1/2) and reoperation 
showed change-points at 17 and 55 cases, respectively, with lymph node harvest showing no 
plateau of the proficiency gain curve, but increasing in a continuous fashion with increasing 
experience.  
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Figure 2: Proficiency gain curve for 30-day all-cause mortality from oesophagectomy for 
cancer with a significant change-point at 15 cases with a reduction from 7.9% to 3.1% 
(P<0.0001).  
 
 
Figure 3: Proficiency gain curve for 5-year all-cause mortality from oesophagectomy for 
cancer with a significant change-point at 59 cases with a reduction from 31.4% to 19.1% 
(P=0.006).  
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5.3. Study III 
From the source cohort of 1820 patients, 59 were excluded as surgeon’s age was not available 
for these patients, leaving 1761 patients included in the final analysis, operated on by 139 
surgeons. RA-CUSUM analysis of 5-year all-cause mortality showed significant change-
points associated with surgeon age at 52 years (downward deflection) and 56 years (upward 
deflection) (Figure 4). Comparison with surgeon age between 52 and 55 years (reference 
category), surgeon age ≤51 years (adjusted HR=1.71, 95%CI 1.01–2.90) and surgeon age ≥56 
years (adjusted HR=2.38, 95%CI 1.38–4.13), were associated with increased 90-day 
mortality. Similarly, when compared with surgeon age between 52 and 55 years (reference 
category), surgeon age ≤51 years (adjusted HR=1.21, 95%CI 1.02–1.43) and surgeon age ≥56 
years (adjusted HR=1.29, 95%CI 1.08–1.55), were associated with increased 5-year all-cause 
mortality. 
 
Figure 4. RA-CUSUM curve for 5-year all-cause mortality, showing change-points at 
surgeon ages of 52 (downward deflection) and 56 years (upward deflection).  
 
5.4. Study IV 
In total 1820 patients who underwent surgery for oesophageal cancer between 1987 and 2010 
in Sweden were included in the study. From Kaplan-Meier survival analysis, university 
hospital status did not affect all-cause 90-day (P=0.115), all-cause 5-year (P=0.460) (Figure 
5) or disease-specific 5-year mortality (P=0.419). Multivariable regression analysis indicated 
improved all-cause 90-day mortality within university hospitals, but the 18% reduction in the 
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point estimate was not statistically significant (HR=0.82, 95% CI 0.61–1.10). However 
multivariable analysis also showed surgery within university hospitals did not improve long-
term mortality; the all-cause 5-year (HR=0.94, 95% CI 0.83–1.05) and disease-specific 5-
year mortality (HR=1.00, 95% CI 0.88–1.14).  
 
Figure 5: Kaplan-Meier survival curve for the effect of surgery for oesophageal cancer 
within university hospitals upon all-cause 5-year survival. 
 
5.5. Study V 
From the FREGAT database, 2439 patients received surgical resection for oesophageal 
cancer and were included in the present study. Of these 208 patients (8.5%) developed a 
clinically significant severe oesophageal anastomotic leak grade III or IV. Factors associated 
with an increased incidence of severe oesophageal anastomotic leak included low volume 
centre (OR=1.92, 95%CI 1.28 to 2.88), cervical location of the anastomosis (OR=1.69, 
95%CI 1.14 to 2.5), upper third tumour location (OR=1.77, 95%CI 1.12 to 2.81) and ASA 
score III or IV (OR=1.63, 95%CI 1.03 to 2.59). Severe oesophageal anastomotic leak was 
associated with reduced overall survival (HR=1.28, 95%CI 1.04 to 1.59) (Figure 6). Severe 
oesophageal anastomotic leak was also associated with significant increases in overall 
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(OR=1.35, 95%CI 1.15 to 1.73), loco-regional (OR=1.56, 95%CI 1.05 to 2.24), and mixed 
tumour recurrence (OR=1.81, 95%CI 1.2 to 2.71).  
 
Figure 6: The overall survival curves in the severe oesophageal anastomotic leak group 
(n=208) and the absence of severe oesophageal anastomotic leak (n=2231). 
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6 METHODOLOGICAL CONSIDERATIONS  
 
6.1. STUDY DESIGN 
Clinically-based research is either experimental or observation in design. Experimental 
clinical research is most commonly as a randomized controlled trial study design. The main 
advantage of this design is the equal distribution of known and unknown confounding factors 
between groups (if they are large enough), ensuring the only exposure differing between the 
groups is the intervention under investigation. However within a surgical or oncology setting, 
strict inclusion criteria employed with the study design, reduces the external validity of the 
study findings to the population of interest at a national or international level. Furthermore 
randomisation can be unethical (as in Study V) or unfeasible (as in Studies II, III and IV), for 
many research questions, thus alternative study designs are required. Observational studies 
when conducted in large national datasets often reflect the true effect size of the exposure 
under investigation, and may be more representative of ‘real life clinical practice’ than a 
randomised controlled trial. The most common types of observational studies are the cohort 
and case-control design. All five studies in this thesis are large cohort studies, which are less 
prone to recall bias compared to case-control studies.  
In a cohort study, individual patients are classified according to the presence or absence of the 
exposure under investigation (exposed and unexposed), and are followed up within the study 
over a period of time to identify the occurrence of the outcome for example mortality. The 
studies included in this thesis can be regarded retrospective as the outcome occurred prior to 
the assembly of patients and classification of their exposure. Main advantages of large 
population-based cohort studies with high participation rates (Studies II, III and IV) are the 
low risk of selection bias and good external validity of the results gained. The disadvantage 
of a cohort study design is the risk of loss to follow-up and missing data, which was 
minimized in the FREGAT (Study I and V) through robust clinical follow-up and in SESS 
(Studies II, III and IV) through careful medical chart review and linkages to nationwide 
complete registries.  
 
6.2. VALIDITY 
Validity is often classified into internal validity, the extent to which the data measures what it 
is intended to measure (unbiased), and external validity, the degree to which results can be 
extrapolated to other settings (generalizability). The studies conducted within this thesis do 
have high internal validity as the datasets utilised are well validated, with robust methods of 
data capture, and the analyses conducted carefully designed to evaluate the primary research 
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question in each case. The external validity of the findings from these studies is unknown 
until they are replicated in other large national datasets. Study II and III concerning surgical 
proficiency gain and surgeon age could be both considered controversial studies because of 
the exposures under study and the results, and further research is required to establish the 
external validity of these findings. Sweden does have a unique healthcare structure and only 
in more recent years has centralised oesophageal cancer surgical services. Therefore it would 
be important to perform studies examining the research questions in studies II and III also in 
countries with a centralised oesophageal cancer service, such as the United Kingdom, as this 
may provide further validity to these findings in future practice in Sweden.  
 
6.3. SELECTION BIAS 
Selection bias is less commonly observed in population-based cohort studies with high 
participation rates, robust inclusion methodology, active data verification at source and 
strategies to minimise missing data. Studies II, III and IV were based on SESS, which is a 
well validated database, capturing 98% of all oesophageal cancer patients treated surgically in 
Sweden. Studies I and V used the FREGAT dataset, which similarly has very robust methods 
of data collection and strategies to minimise missing data. However the FREGAT dataset 
only includes patients managed at highly experienced French-speaking European 
Oesophageal Cancer Centres, and thus the results from these studies may not have external 
validity if the results are extrapolated to the entire France. Furthermore in Study I patients 
undergoing salvage oesophagectomy are by definition a selected group of patients, and thus 
as stated in the manuscript, the results of this study can only be applied in high volume 
centres with strict patient selection.  
 
6.4. INFORMATION BIAS 
Information bias is essentially misclassification or miscoding of data related to the exposure 
or outcome related to the individuals under investigation within the study. It may be 
differential (non-random) when the misclassification systematically differs between the study 
groups and this may lead to bias of the outcome in either direction from the misclassification. 
Information bias may also be non-differential (random) when the misclassification does not 
differ between the groups, leading the attenuation of potential associations and thus bias 
towards the null.  
For both the FREGAT and SESS datasets, information from hospital medical records was 
collected using a detailed predefined protocol. For both datasets, researchers involved 
ensured that the data collected were correct and complete, in order to reduce misclassification 
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and information bias. However it must be acknowledged that within hospitals coding of 
medical comorbidities and complications including their severity may be subject to biases of 
individual inputting the data. In SESS, more than one researcher has reviewed the most 
important variables to reduce misclassification. In more recent years, consensus groups have 
sought to define complications following oesophagectomy to reduce this aspect of 
information bias in future oesophageal cancer surgery studies [67, 68].  
 
6.5. CONFOUNDING 
Confounding factors are factors that are associated with both the exposure and the outcome 
and may influence the findings of the study, without being part of the direct causal pathway 
between exposure and outcome. In the studies conducted in this thesis, all known established 
confounding factors that may influence the outcomes studied were adjusted for in the analysis 
to counteract confounding. However as stated in the limitations paragraph of all the studies, 
unmeasured potential confounding, e.g. by obesity, smoking or other lifestyle factors could 
have introduced residual unmeasured confounding, which cannot be ruled out in 
observational studies. Importantly though, given the size of the datasets used in these studies, 
the influence of these unmeasured confounding factors is likely to be equally distributed 
between the exposure groups and thus unlikely to be a primary factor influencing the 
outcomes.  
 
6.6. PRECISION 
Precision describes the degree of random error within a study. The size of random error can 
be reduced by increasing the sample size and often narrows the confidence interval for the 
effect size. The hazard or odds ratio results in the studies in this thesis were presented with 
95% confidence intervals, which indicate that replication of the study would generate a point 
estimate included within the confidence interval 95% of the time. The P values provided in 
several of the studies, describe the probability of the result being due to chance, which was 
set at 0.05 to assign statistical significance to the results, accepting 5% of the results may be 
secondary to chance. In this situation the null hypothesis could be rejected when it is true 
(type I error), or not rejected when it is false (type II error).  
The P value to assign statistical significance to the studies in this thesis was set at 0.05, 
suggesting the results had to show good precision (reducing the risk of type II error). Several 
mechanisms reduced the chance of type II error within the studies; (i) clearly predefined 
hypotheses, (ii) large national or regional cohorts and (iii) the use of clinically relevant factors 
in multivariable analyses to limit the effects of multiple testing.   
41
 30 
 
7 GENERAL DISCUSSION  
 
7.1. STUDY I 
This study showed short- and long-term mortality and cancer recurrences, were similar 
between patients undergoing salvage oesophagectomy after definitive chemoradiotherapy 
compared with planned oesophagectomy after neoadjuvant chemoradiotherapy. Importantly 
surgery in high volume centres and following a lower total radiation dose, were associated 
with a reduced postoperative mortality and morbidity rate in the salvage oesophagectomy 
group.  
The results from this cohort study contradict a meta-analysis I previously published [38], 
which is likely due to two main reasons. Firstly in this cohort study, approximately 80% of 
patients underwent salvage oesophagectomy at experienced centres, and benefited from 
discussion within multidisciplinary team meetings ensuring appropriate patient selection and 
standardised postoperative protocols to optimise recovery [69]. Secondly, the mediation 
radiation dose in this cohort study in patients receiving definitive chemoradiotherapy was 
50Gy, much lower than those in the majority of studies included in the meta-analysis [38].  
Patients with no tumour response following definitive chemoradiotherapy had a reduced 
overall and disease-free survival compared with those with recurrent disease. This may 
suggest that tumours that persisted following definitive chemoradiotherapy have an 
underlying more aggressive pathology. Therefore clearly the early identification of patients 
not responding to multi-modality therapy is a priority area for ongoing research with several 
research groups focusing on the use of positron emission tomography to identify the 
metabolic activity of the tumour [70,71], or contrast enhanced MRI or repeat endoscopic 
ultrasound with biopsies.  
 
7.2. STUDY II 
Study II identified that gaining proficiency in performing resection of oesophageal cancer is 
associated with measurable changes in short- and long-term mortality. The length of the 
proficiency-gain curve was limited for short-term mortality but greater for long-term 
mortality.  
The shorter length of proficiency-gain curve regarding short-term survival demonstrated in 
the present study parallels previous publications concerning open oesophagectomy from 
single centres [72] and a national study of minimally invasive oesophagectomy in England 
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[42]. Even though this period of proficiency gain was short, 15 cases for 30-day all-cause 
mortality, there was substantial reduction in 30-day mortality, relative risk reduction of 61%. 
Similarly the longer period of proficiency gain for 5-year all-cause mortality (59 cases), was 
associated with substantial effects on patient mortality, with a relative risk reduction of 39%. 
The differences in the length of proficiency gain curve for short- and long-term mortality, 
within this study may be explained by the psychological primary concern of the 
independently practicing surgeon. Initially the focus is on short-term outcomes, ensuring a 
low anastomotic leak rate and short-term mortality, however in the longer-term once the 
short-term outcomes are acceptable they begin to focus on the oncological quality of their 
resection, improving cancer outcomes for their patients.   
Surgical learning at the expense of patient mortality is morally unacceptable, and must be 
addressed at a national level before surgeons practice established procedures independently or 
introduce new techniques adding to their proficiency gain curve. Structured based training 
programs with competency based assessments, and a long period of mentorship during the 
early stages of independent practice may reduce any adverse effects of surgical proficiency 
gain to patients [73,74,75].     
 
7.3. STUDY III 
Study III indicated the importance of surgeon age as a prognostic factor short and long-term 
mortality from oesophagectomy for oesophageal cancer. The “optimal” surgeon age in 
Sweden for oesophageal cancer surgeons from the present study is between 52 and 56 years. 
Before this age, surgeons are gaining surgical proficiency, paralleling the results of Study II 
[76]. After this age, there is a decline in surgical performance as illustrated by an increase in 
short- and long-term mortality.  
Oesophageal cancer surgery is a highly psychologically and technically demanding 
procedure, with long periods of intense concentration and high level physical performance 
required. An analogy may be drawn with other technical professions such as athletes or 
musicians, who have a short time period of optimal performance, when the individual has 
sufficient expertise and is at the peak of their technical abilities to maximise their level of 
performance.  
Clearly there is wide range in how individual surgeons age, and in their physical and 
psychological abilities at different ages, therefore compulsory retirement ages, or relying on 
individual surgeons to recognise any change in their abilities is unfair. Individual 
competency-based assessments with human reliability analysis [77, 78, 79] may be able to 
identify changes in operative performance before patient harm occurs.    
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7.4. STUDY IV 
Study IV demonstrated a negative finding, and disproved the hypothesis that oesophagectomy 
performed within university hospital settings reduced the risk of long-term mortality after 
adjustment for surgeon volume (and other potential confounders). An important limitation of 
this study was that the majority of cases performed by higher volume surgeons were 
performed in university hospitals, highlighting that in clinical practice these two variables are 
closely linked.  
This study demonstrates the importance of surgeon volume in the long-term outcome of 
patients undergoing oesophageal cancer surgery, paralleling previous studies [80, 81]. The 
key principles of high quality oesophageal cancer surgery with strong prognostic influence, 
more commonly employed by high volume surgeons, include minimizing blood loss, 
reducing complications and reducing positive resection margin incidence [80, 81, 82]. In the 
SESS dataset, university hospital status and surgeon volume were closely linked, and given 
the pattern of centralisation of high-risk surgery such as oesophagectomy, this is likely to be 
the case internationally. University hospitals may in the future provide an ideal environment 
for surgeons to be trained in the key principles of high quality oesophageal cancer surgery 
before embarking upon independent practice [83].  
 
7.5. STUDY V 
The most important findings from Study V, were that severe oesophageal anastomotic leak 
after oesophagectomy is associated with decreased overall and disease-specific survivals and 
an increase in overall, loco-regional, and mixed cancer recurrences. Important factors 
associated with severe oesophageal anastomotic leak included low hospital volume, cervical 
anastomosis, upper third tumour location and ASA grade III or IV.  
Previous smaller studies have been inconsistent in their findings concerning the prognostic 
influence of anastomotic leak following oesophagectomy [84–88]. However the present study 
is the largest in the area, and identifies a strong association between severe oesophageal 
anastomotic leak and decreased prognosis, which parallels previous research from colorectal 
cancer surgery [89]. The mechanism of increased loco-regional recurrence following severe 
oesophageal anastomotic leak may parallel that seen for colorectal leak, with the leakage of 
enteric contents creating a pro-inflammatory environment. The release of acute phase 
reactants and cytokines, IL-32, TNF-alpha, IL-6 and IL-1beta, may promote tumour 
proliferation following the spillage of viable tumour cells from anastomotic lines following 
leak [90, 91, 92].  
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Tumour and patient factors associated with severe oesophageal anastomotic leak really 
identified established risk factors, which may compromise the gastric micro-circulation 
promoting anastomotic leak. The best established of these is the cervical location to the 
anastomosis, which commonly places the anastomosis and gastric circulation on a stretch and 
thus has been suggested to lead to increased incidence of anastomotic leak [93]. The 
association of low hospital volume with increased severe oesophageal anastomotic leak 
provides further evidence of the prognostic importance of hospital volume in high risk cancer 
surgery, and the need for centralisation of oesophagectomy to high volume centres [94, 95].   
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8 CONCLUSIONS  
 
• Salvage oesophagectomy after definitive chemoradiotherapy can offer acceptable short- 
and long-term outcomes in selected patients at experienced oesophageal cancer centres.  
• The period during which surgeons gain proficiency in performing oesophagectomy for 
cancer is associated with substantial adverse effects upon short- and long-term mortality.  
• The optimal surgeon age in performing oesophagectomy in Sweden is between 51 and 56 
years. Outside of this age period, increases in short- and long-term mortality are noted, as 
surgeons are still gaining experience or maybe experiencing decline in their technical 
abilities.  
• Surgery performed in university hospitals has no independent improvements in long-term 
mortality from oesophagectomy after adjustment for surgeon volume and other measured 
confounders.  
• Severe oesophageal anastomotic leak following oesophagectomy for cancer, adversely 
impacts cancer prognosis with a decrease in overall and disease-free survival and an 
increasing in overall, loco-regional and mixed cancer recurrence.  
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9 FUTURE RESEARCH  
 
Strategies for organ preservation using combined oncological-targeted therapies in the 
management of oesophageal cancer may be the next step for clinical researchers. A large 
multi-centre randomised controlled trial comparing two strategies for locally advanced 
oesophageal cancer is needed; (i) definitive chemoradiotherapy with salvage oesophagectomy 
for persistent or recurrent disease vs. (ii) neoadjuvant chemoradiotherapy and planned 
oesophagectomy. Given the radio-sensitivity of oesophageal squamous cell carcinoma, a 
study focused on this histological subtype would be of great interest.  
Studies II and III have suggested that specific surgeon related factors such as a proficiency 
gain and surgeon age, can adversely impact patient mortality from oesophagectomy. Future 
research is needed to create standardised competency based assessments for oesophagectomy 
with sufficient sensitivity to identify changes in a surgeon’s proficiency or technical ability 
before patient harm is observed. Importantly the period of proficiency gain required for the 
adequate performance of a new surgical technique may require careful investigation before 
that technique is investigated in a randomised trial setting. Competency based assessments 
may also serve as a test to allow surgeon entry into randomised controlled trials to prevent 
poor outcomes from the new interventional arm associated with the surgical proficiency gain 
period.  
The importance of university hospital status on long-term outcome from oesophagectomy 
does require further investigation with a dataset where university hospital status and surgeon 
volume are less closely linked. A further area of investigation may include university 
hospitals with active participation in randomised controlled trials, testing the hypothesis that 
active trial participation can raise the clinical outcomes of an individual hospital through 
exposure to novel therapies and close patient monitoring.  
The mechanism through which oesophageal anastomotic leak increases loco-regional 
recurrence and decreases long-term survival is an important area for future research. This 
may be a result of the proinflammatory environment with upregulation of cytokines 
stimulating tumour growth, or this may also involve an interaction with the host microbiome 
given the leakage of enteric comments. The complex interplay between the patient 
microbiome, oesophageal cancer and postoperative complications with immune effects is an 
extremely interesting area for future research.   
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